Results 141 to 150 of about 131,813 (277)

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Hepatitis A vaccination.

The Practitioner, 1993
The safety and immunogenicity of an inactivated hepatitis A virus vaccine were assessed in 101 healthy adults. Seronegative persons with normal serum aminotransferase levels were grouped according to age: Group 1 (n = 24) and group 3 (n = 22) were between 18 and 40 years of age, and group 2 (n = 25) and group 4 (n = 30) were older than 40 years. Groups
M J, Tong, R L, Co, C, Bellak
openaire   +3 more sources

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, EarlyView.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

Preclinical evaluation of therapeutic vaccines for chronic hepatitis B that stimulate antiviral activities of T cells and NKT cells

JHEP Reports
Background & Aims: Liver diseases resulting from chronic HBV infection are a significant cause of morbidity and mortality. Vaccines that elicit T-cell responses capable of controlling the virus represent a treatment strategy with potential for long ...
Anna H. Mooney, Sarah L. Draper, Olivia K. Burn, Regan J. Anderson, Benjamin J. Compton, Chingwen Tang, Kathryn J. Farrand, Pietro Di Lucia, Micol Ravà, Valeria Fumagalli, Leonardo Giustini, Elisa Bono, Dale I. Godfrey, William R. Heath, Weiming Yuan, Francis V. Chisari, Luca G. Guidotti, Matteo Iannacone, John Sidney, Alessandro Sette, Shivali A. Gulab, Gavin F. Painter, Ian F. Hermans   +22 more
doaj   +1 more source

The Swiss Haemophilia Registry–Report From the First 8 Years

Haemophilia, EarlyView.
ABSTRACT Introduction Patient registries capture disease related information and provide a valuable source for real‐world data on rare diseases and their management. The Swiss Haemophilia Registry (SHR) was established in 2015 on the basis of a new Swiss federal human research act.
Alessandra Bosch, Lorenzo Alberio, Pierre Fontana, Lukas Graf, Johanna A. Kremer Hovinga, Nicolas von der Weid, Mattia Rizzi, Manuela Albisetti, the Swiss Haemophilia Network   +8 more
wiley   +1 more source

Perspectives on Pertussis Prevention

Acta Paediatrica, EarlyView.
Ulrich Heininger
wiley   +1 more source

Suppression of Indoleamine 2,3‐Dioxygenase Enhances Immune Responses to the Therapeutic Vaccine for Chronic Hepatitis B

Hepatology Research, EarlyView.
Indoleamine 2,3‐dioxygenase (IDO) activity modulates immune responses to the therapeutic HBV vaccine NASVAC. Genetic or pharmacological suppression of IDO enhanced vaccine efficacy in mice, and lower serum kynurenine levels predicted favorable responses in humans, suggesting IDO as both a therapeutic target and a biomarker.
Yohei Shirakami, Soranobu Ninomiya, Takayasu Ideta, Ayumu Kanbe, Toshihide Maeda, Daisuke Minowa, Daisuke Taguchi, Masaya Kubota, Hiroyasu Sakai, Kenji Imai, Yasuko Yamamoto, Hiroyasu Ito, Kuniaki Saito, Osamu Yoshida, Yoichi Hiasa, Masahito Shimizu   +15 more
wiley   +1 more source

Chip Shots: Association Between the State Children's Health Insurance Programs and Immunization Coverage and Delivery [PDF]

By age two a child who is up to date for immunizations will have received up to 19 shots delivered over eight visits at a market cost of $525 dollars for the vaccines alone, a far more expensive and demanding regimen that the 8 shots received in 1987. In
Andrew Racine, Ted Joyce
core  

Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan

Hepatology Research, EarlyView.
Hepatitis B is a viral liver infection that can become chronic, increasing the risk of developing liver cancer and liver failure. Because current treatments rarely cure these problems, researchers are now focusing on a functional cure in which the virus becomes undetectable in blood and stays that way, even after the treatment ends.
Yutaka Handa, Ethan Yichen Lee, Yasuhito Tanaka   +2 more
wiley   +1 more source

HIV‐1 viral load and reservoir size remain stable following SARS‐CoV‐2 mRNA vaccination in people with HIV

HIV Medicine, EarlyView.
Abstract Background The potent immunogenicity of mRNA vaccination raised concerns about its impact on HIV‐1 viral load (VL) and reservoir size in people with HIV, which could drive vaccine hesitancy. As part of a prospective clinical trial, we investigated whether SARS‐CoV‐2 mRNA vaccination induced changes in VL and reservoir size after a 1‐year three‐
Oscar Kieri, Bianca B Jütte, Jan Vesterbacka, Soo Aleman, Hans‐Gustaf Ljunggren, Marcus Buggert, J Peter Svensson, Anders Sönnerborg, Piotr Nowak   +8 more
wiley   +1 more source